NasdaqGS:SYREBiotechs
Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?
Spyre Therapeutics stock reacts to new SPY772 program and SKYLIGHT trial launch
Spyre Therapeutics (SYRE) is in focus after the company launched its SPY772 combination program and began SKYLIGHT, a Phase 2 proof of concept trial in Hidradenitis Suppurativa.
Both efforts target dual inhibition of TL1A and IL-17A/F in moderate to severe HS. The approach uses SPY072 alongside background bimekizumab therapy for around 150 adult participants.
See our latest analysis for Spyre Therapeutics.
Spyre...